Genmab A/S (GMAB), Monday announced the decision to discontinue further clinical development of acasunlimab to focus on programs with the highest potential impact, such as EPKINLY, petosemtamab and rinatabart sesutecan.
The decision, which is in line with the company's portfolio prioritization and capital allocation framework, is expected to have no impact on full-year 2025 financial guidance.
"Although the data have been encouraging, the compelling opportunities we see in our late-stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders," CEO Jan van de Winkel explained.
In the pre-market hours, Genmab's stock is trading at $32.72, down 2.09 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.